PCVX - Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Vaxcyte (PCVX) is positioned for long-term growth due to its late-stage vaccine programs, particularly VAX-31 and VAX-A1, and expanded manufacturing capabilities. Analysts project significant revenue growth by 2029, with a consensus price target of $109, implying the stock is currently undervalued. However, the pre-revenue company faces risks including rising R&D costs, potential underperformance of vaccine candidates, and intense competition in the vaccine market.
PCVX - Vaxcyte Inc Volatility & Greeks
This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownership, and price performance over different periods. The data indicates Vaxcyte's current financial health and market position within the biotechnology sector.
PCVX - Vaxcyte Inc Options
The article provides comprehensive financial data and trading information for Vaxcyte Inc (PCVX), including its last close price, market capitalization, earnings per share, sales figures, and various performance metrics. It also details insider and institutional ownership, short interest, and analyst recommendations, offering a snapshot of the company's current market position and potential outlook.
Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup.
Vaxcyte's stock performance is primarily driven by its pneumococcal vaccine pipeline, clinical milestones, and company disclosures. The company, a US-listed vaccine developer on Nasdaq, has its investor relations information as the main public reference point. Its market valuation is less tied to immediate revenue and more to clinical trial updates, regulatory progress, and financing decisions.
PCVX - Vaxcyte Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Vaxcyte Inc (PCVX). It details various financial metrics, including market capitalization, income, sales, EPS, P/E ratios, and stock performance, alongside insider and institutional ownership statistics. The data highlights the company's current financial health and market position as of July 2, 2024.
Have Insiders Sold Vaxcyte Shares Recently?
A recent insider transaction at Vaxcyte (NASDAQ:PCVX) involved Co-Founder Grant Pickering selling US$1.3m worth of shares at an average price of US$55.22, reducing his holding by 5.4%. This was the largest insider sale in the last year, occurring near the current share price of US$56.08, but there has been no insider buying in the past year. While insider ownership is not particularly high at 0.6%, the company's financial and operational risks should also be considered.
Have Insiders Sold Vaxcyte Shares Recently?
This article analyzes recent insider selling activity at Vaxcyte (NASDAQ:PCVX) by examining transactions over the past year. It highlights that insiders have sold 3.5% of their holdings, totaling approximately $12 million, over the last three months, while not making any purchases. The article discusses factors influencing insider selling and suggests that investors should consider both insider activity and the company's valuation.
Form 144 Vaxcyte For: 1 July By Investing.com
The article announces the filing of Form 144 for Vaxcyte on July 1st. It also features current market data for indices, commodities, bonds, and shares, along with trending news and top stock movers, including Vaxcyte's stock performance.
PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items
A recently filed Form 144 from Vaxcyte, Inc. (PCVX) indicates that director James Wassil completed three sales of 2,250 shares each on April 1, May 1, and June 1, 2026, generating gross proceeds of $131,475.60, $127,870.65, and $111,416.62 respectively. The filing also details upcoming issuances to Wassil, including 724 RSUs vesting on September 2, 2025, 1,010 RSUs vesting on September 7, 2025, and 516 shares from a cash exercise of stock options on July 1, 2026. This is a routine notice concerning affiliate sales and scheduled issuances.
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell Small Cap Comp Growth Benchmark
Vaxcyte, Inc. (NasdaqGS: PCVX) has been added to the Russell Small Cap Comp Growth Benchmark. This news follows a series of recent developments for the company, including board changes, insider stock sales, and progress in its vaccine trials for various bacterial diseases. The company is actively developing several vaccine candidates, including VAX-31 and VAX-24 for pneumococcal disease, and VAX-A1 and VAX-GI for Group A Strep and Shigella, respectively.
Price to earnings forward of Vaxcyte, Inc. – NASDAQ:PCVX
This page from TradingView provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX), specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data and trading platform.
10 Health Care Stocks With Whale Alerts In Today’s Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks. It details bullish, bearish, and neutral sentiment trades on specific call and put contracts for companies like Vaxcyte, SELLAS Life Sciences, Hims & Hers Health, and others. The report provides key information for each options trade, including expiration dates, strike prices, total trade prices, open interest, and volume.
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2000 Growth Benchmark
Vaxcyte, Inc. (NasdaqGS: PCVX), a clinical-stage vaccine company, has been added to the Russell 2000 Growth Benchmark. The company is focused on engineering high-fidelity vaccines to combat bacterial diseases, with a pipeline that includes candidates for pneumonia and Group A Strep infections. The article also provides recent news on board changes, insider transactions, and clinical trial progress.
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing
An insider at Vaxcyte, Inc. recently sold shares totaling $1,338,270, as reported in a new SEC filing. This transaction occurred on June 29, 2026, and follows a previous insider share sale on June 22, 2026. Vaxcyte is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases.
Is Vaxcyte’s (PCVX) Russell Index Debut Quietly Reframing Its Long‑Term Governance And Growth Story?
Vaxcyte (PCVX) was recently added to several Russell growth indices and refreshed its board, with Moncef Slaoui joining as an independent director and Jacks Lee transitioning to a manufacturing consultant role. While these moves are positive for profile and governance, the primary investment narrative still hinges on upcoming Phase 3 data for VAX-31 and managing increasing cash burn before revenue generation. The article emphasizes that manufacturing execution is crucial for Vaxcyte's long-term success given its significant investment in U.S. capacity.
Price to sales forward of Vaxcyte, Inc. – NASDAQ:PCVX
This article from TradingView provides financial data for Vaxcyte, Inc. (NASDAQ: PCVX), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or a data-driven page, presenting numerical values and change percentages for this financial metric under a "Financials" tab. The content also lists various resources and services offered by TradingView.
Understanding Momentum Shifts in (PCVX)
This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) using AI models, highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional short setup risk-reward ratio. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing specific entry zones, targets, and stop losses. The report emphasizes the predictive AI's ability to add alpha, reduce beta, and control risk for investors.
Enterprise value to EBIT forward of Vaxcyte, Inc. – NASDAQ:PCVX
This article provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX) on TradingView, specifically focusing on its enterprise value to EBIT forward. It indicates that the market is closed with no trades, and the content is primarily a data page rather than an analytical piece.
Price to book forward of Vaxcyte, Inc. – NASDAQ:PCVX
This article provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX) on TradingView, specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview, market data, and various tools available on the TradingView platform for analyzing stocks.
Price to sales forward of Vaxcyte, Inc. – XETR:5VA
This article provides financial information for Vaxcyte, Inc. (XETR:5VA), focusing on its forward price-to-sales ratio. It appears to be an excerpt from a financial data platform, likely TradingView, offering an overview of the company's financial metrics. The primary content refers to "Price to sales forward" data without providing specific figures in this snippet.
Price to earnings forward of Vaxcyte, Inc. – XETR:5VA
This page provides information about the forward price-to-earnings ratio for Vaxcyte, Inc. (XETR:5VA). It indicates that the specific financial data for this metric is presented on the platform, alongside general market and company information.
Price to book forward of Vaxcyte, Inc. – XETR:5VA
The article provides financial information for Vaxcyte, Inc. (XETR:5VA) focusing on its price-to-book forward ratio. It highlights the stock's status and points to various data sources like ICE Data Services and FactSet for market and reference data, respectively. The content appears to be an excerpt from a financial data platform.
Vaxcyte CEO Grant Pickering sells $1.34m in company shares By Investing.com
Vaxcyte CEO Grant Pickering sold $1.34 million worth of company common stock on June 26, 2026, under a pre-arranged trading plan. The shares were sold at prices between $54.222 and $56.266, following a 72% surge in Vaxcyte's stock over the past year. This transaction included both direct sales by Mr. Pickering and indirect sales through trusts for his children.
Vaxcyte (PCVX) CEO and family trusts sell 24,237 shares under 10b5-1 plan
Vaxcyte, Inc. CEO Grant Pickering and family trusts sold a total of 24,237 shares of Common Stock on June 26, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026, and involved both directly held shares and those held by trusts for his children. After the direct sales, Pickering held 468,020 shares directly, with additional indirect holdings through the family trusts.
Grant Pickering sells 22,461 PCVX shares (UBS broker) (PCVX)
A recent Form 144 SEC filing for Vaxcyte, Inc. (PCVX) details proposed resales of Common stock through UBS Financial Services and reports recent affiliate sales. Grant Pickering sold 22,461 shares for over $1.1 million, and two Delaware trusts associated with the Pickering family each sold 1,000 shares for $52,500. The filing also lists various RSU vests and Founder Shares as securities to be sold.
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110
Needham has reiterated its Buy rating on Vaxcyte (PCVX.US) and maintained its target price at $110. This indicates ongoing confidence from the analyst firm in the company's prospects.
Vaxcyte, Inc. Actuals & Estimates (NASDAQ:PCVX)
This article provides current financial actuals and estimates for Vaxcyte, Inc. (PCVX), including its stock price performance, analyst forecasts, and historical highs and lows. It also details the company's financial reports, market capitalization, earnings, revenue, and employee count, alongside guidance on how to trade its stocks and investment advice.
PCVX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Vaxcyte, Inc. (PCVX) stock, including analyst price targets, historical performance, and financial data. Analysts have a maximum price estimate of $163.00 and a minimum of $67.00 for PCVX. The company's stock has seen significant increases over the past week, month, and year, and its next earnings report is scheduled for August 12, 2026.
Vaxcyte, Inc. Actuals & Estimates (XETR:5VA)
This article provides an overview of Vaxcyte, Inc. (XETR:5VA) financials and analyst estimates, including price targets, historical stock performance, and upcoming earnings dates. It highlights details such as the company's Q1 2026 earnings surprise, revenue, net income, and employee count. The piece also answers frequently asked questions about Vaxcyte stock.
Moncef Slaoui joins Vaxcyte (NASDAQ: PCVX) board as director
Vaxcyte, Inc. announced that Moncef Slaoui has been appointed as a Class II independent director to its board, effective June 17, 2026, with his term extending until the 2028 annual meeting. This appointment follows the retirement of long-serving director Jacks Lee on the same day, who will continue to consult for the company on strategic supply and manufacturing. Slaoui will be compensated under Vaxcyte's non-employee director program, which includes an annual equity grant valued at $430,000.
Vaxcyte Announces Board Transition and New Director Appointment
Vaxcyte (PCVX) announced board changes, with director Jacks Lee retiring on June 17, 2026, to become a consultant, and Moncef Slaoui being appointed as an independent Class II director. Slaoui's term runs through the 2028 annual meeting, and he will receive standard non-employee director compensation. An analyst has a Buy rating on PCVX stock with a $163.00 price target, although Spark, TipRanks’ AI Analyst, rates PCVX as Neutral due to lack of revenue, widening losses, and increasing cash burn.
Vaxcyte announces board changes with retirement of Jacks Lee and appointment of Moncef Slaoui
Vaxcyte, Inc. announced board changes, including the retirement of Jacks Lee from its board of directors, effective June 17. Lee will continue to advise the company as a consultant. Concurrently, Moncef Slaoui was appointed as a Class II director, effective immediately, and will receive compensation consistent with the company's non-employee director program.
Form 8K Vaxcyte Inc For: 23 June By Investing.com
This article announces that Vaxcyte Inc. filed a Form 8K on June 23. It includes the stock symbol PCVX and mentions a 3.68% increase in its value. The content primarily focuses on the filing of this financial document.
Form 8K Vaxcyte Inc For: 23 June By Investing.com
This article announces that Vaxcyte Inc. filed a Form 8K on June 23. The filing is brief and primarily focuses on the company's regulatory disclosure without providing specific details about the content of the 8K itself. The stock symbol PCVX is mentioned with a slight decrease in price.
Moncef Slaoui gets 26,061 Vaxcyte (PCVX) options at $52.11 strike
Vaxcyte, Inc. director Moncef Slaoui has been granted 26,061 stock options with an exercise price of $52.11 per share, expiring on June 22, 2036. This compensation-related grant will vest over 36 months, with one-third vesting on June 17, 2027, and the remainder in equal monthly installments, contingent on his continued service. This transaction is classified as an award, not an open-market purchase or sale.
Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership
Vaxcyte director Moncef Slaoui has filed a Form 3, an initial statement of beneficial ownership, disclosing that he holds no securities in the company. This filing indicates zero beneficial ownership of Vaxcyte common stock and reports no purchase or sale transactions, establishing his starting position as an insider. The Form 3 clarifies that he directly owns 0 shares.
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Vaxcyte (PCVX) has initiated a Phase 1 clinical trial for VAX-A1, an experimental vaccine targeting Group A Streptococcus, a disease for which no approved vaccine currently exists. The company estimates Group A Strep causes 800 million illnesses globally annually, ranging from strep throat to life-threatening infections. The trial will enroll 80 healthy adults in Australia to assess the vaccine's safety and tolerability across different dose levels.
Vaxcyte (PCVX) Stock Could Be 52.8% Undervalued After VAX A1 Enters Phase 1
Vaxcyte (PCVX) has initiated a Phase 1 trial for its investigational Group A Streptococcus vaccine, VAX-A1. Despite recent positive share price movements over the past month and year, the stock is considered significantly undervalued, with a fair value estimate of $109 against its current price of $51.44. However, investors are cautioned to consider risks like potential VAX-31 data disappointments or high manufacturing costs.
Vaxcyte (PCVX) Stock Could Be 52.8% Undervalued After VAX A1 Enters Phase 1
Vaxcyte (PCVX) has initiated a Phase 1 trial for its investigational Group A Streptococcus vaccine, VAX-A1, marking a new clinical milestone. Despite recent share price gains, the stock appears significantly undervalued at $51.44 compared to an analyst target and intrinsic value of $109, suggesting potential upside for investors. However, the company's valuation hinges on successful VAX-31 trial data and manageable manufacturing costs, with risks and rewards needing further assessment by investors.
Vaxcyte CEO Grant Pickering sells $1.28m in stock By Investing.com
Vaxcyte CEO Grant Pickering sold approximately $1.28 million worth of company stock through a pre-arranged trading plan. The transactions, involving 24,461 shares, occurred on June 18, 2026, at prices around $52.50 per share, close to its InvestingPro Fair Value. Concurrently, Mr. Pickering also exercised stock options to acquire 225 shares for $402.
UBS Lists Multiple PCVX Share Lots for Sale (NASDAQ: PCVX)
UBS Financial Services has filed a Form 144 notice, indicating proposed sales of Vaxcyte, Inc. (NASDAQ: PCVX) common stock. These sales are associated with option exercises and the vesting of Restricted Stock Units (RSUs), detailing specific share blocks and transaction dates without disclosing aggregate proceeds or pricing. This procedural filing ensures transparency regarding the intent to sell restricted or control securities.
Vaxcyte president and CFO sells $530,000 in company stock By Investing.com
Vaxcyte's President and CFO, Andrew Guggenhime, sold 10,000 shares of company stock for $530,000 on June 18, 2026, as part of a Rule 10b5-1 trading plan. The sale followed his exercise of stock options to acquire the same number of shares for $53,500. Despite the sale, Guggenhime still holds a significant number of shares and options, while Vaxcyte's stock has seen a 54% return over the past year and the company is financially flexible with ongoing clinical trials.
Vaxcyte president and CFO sells $530,000 in company stock
Vaxcyte's President and CFO, Andrew Guggenhime, sold 10,000 shares of company stock for $530,000 on June 18, 2026, as part of a Rule 10b5-1 trading plan. On the same day, he acquired 10,000 shares through stock option exercise at a lower price. The company's stock has performed well, and Vaxcyte is advancing various vaccine candidates through clinical trials, including VAX-31 and VAX-A1.
Vaxcyte (PCVX) CFO sells 10K shares under 10b5-1 plan, holds 166K+
Vaxcyte's President and CFO, Andrew Guggenhime, executed a pre-planned transaction on June 18, 2026. He exercised stock options for 10,000 shares at $5.35 per share and subsequently sold 10,000 shares at $53.00 per share under a Rule 10b5-1 trading plan. Following these transactions, Guggenhime holds over 166,000 shares, directly and indirectly.
[144] Vaxcyte, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Vaxcyte, Inc. (PCVX) dated June 18, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $530,000, acquired through the exercise of stock options. This sale, made via UBS Financial Services, Inc., was processed on the NASDAQ exchange.
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
Vaxcyte shareholders have re-elected three Class III directors and approved governance measures at their annual meeting on June 15, 2026, including ratifying Deloitte & Touche LLP as independent auditor and approving executive compensation. An analyst has rated Vaxcyte stock (PCVX) as a Buy with a $116.00 price target, while TipRanks' AI Analyst, Spark, considers PCVX a Neutral due to lack of revenue, accelerating losses, and heavy cash burn despite a strong balance sheet. The company is characterized as a biotechnology firm with a current market cap of $6.85 billion.
Vaxcyte (NASDAQ: PCVX) CEO sells 24,461 shares under 10b5-1 plan
Vaxcyte CEO Grant Pickering sold 24,461 shares of Common Stock on June 18, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales, at approximately $52.50 per share, included shares from his direct holdings and two children's trusts. Following these transactions, Pickering directly holds 496,939 shares and indirectly holds 135,215 shares through trusts.
Vaxcyte CEO Grant Pickering sells $1.28m in stock By Investing.com
Vaxcyte Inc.'s CEO, Grant Pickering, sold approximately $1.28 million worth of common stock on June 18, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred at prices around $52.50-$52.51 per share, near the stock's InvestingPro Fair Value, following a 54% return over the past year. Concurrently, Pickering exercised stock options to acquire 225 shares at $1.79 per share.
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Vaxcyte Inc (PCVX), noting that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder on a financial analysis platform, indicating the absence of certain financial specifics for Vaxcyte.
Vaxcyte Inc (PCVX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Vaxcyte Inc (PCVX) focusing on its dividend and stock split history, noting that no dividend data is available for the past five years. It presents current stock performance details like market capitalization and real-time quotes. The page essentially serves as a data placeholder for the company's financial events.
